Johnson & Johnson $JNJ Stake Boosted by Nwam LLC

Nwam LLC raised its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 106.0% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 28,715 shares of the company’s stock after purchasing an additional 14,778 shares during the period. Nwam LLC’s holdings in Johnson & Johnson were worth $5,467,000 as of its most recent SEC filing.

A number of other large investors also recently modified their holdings of the business. Norges Bank acquired a new position in Johnson & Johnson in the second quarter valued at approximately $4,877,174,000. Laurel Wealth Advisors LLC boosted its position in Johnson & Johnson by 15,040.6% during the 2nd quarter. Laurel Wealth Advisors LLC now owns 7,420,699 shares of the company’s stock valued at $1,133,512,000 after purchasing an additional 7,371,687 shares during the period. Vanguard Group Inc. grew its stake in Johnson & Johnson by 1.3% during the 2nd quarter. Vanguard Group Inc. now owns 237,047,859 shares of the company’s stock worth $36,209,060,000 after buying an additional 3,085,180 shares during the last quarter. Geode Capital Management LLC lifted its stake in Johnson & Johnson by 2.1% in the second quarter. Geode Capital Management LLC now owns 60,609,476 shares of the company’s stock valued at $9,227,988,000 after buying an additional 1,225,676 shares during the last quarter. Finally, Legal & General Group Plc boosted its holdings in shares of Johnson & Johnson by 6.2% during the second quarter. Legal & General Group Plc now owns 18,917,274 shares of the company’s stock valued at $2,889,614,000 after acquiring an additional 1,097,855 shares during the period. 69.55% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of research firms have issued reports on JNJ. Argus set a $210.00 target price on shares of Johnson & Johnson in a research note on Wednesday, October 15th. Loop Capital set a $190.00 price target on Johnson & Johnson in a research note on Wednesday, October 22nd. Johnson Rice set a $190.00 price objective on shares of Johnson & Johnson and gave the company a “hold” rating in a research note on Wednesday, October 22nd. Royal Bank Of Canada set a $240.00 target price on shares of Johnson & Johnson in a research report on Wednesday, December 17th. Finally, Weiss Ratings reissued a “buy (b)” rating on shares of Johnson & Johnson in a research note on Friday, October 31st. Four analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and nine have issued a Hold rating to the company. Based on data from MarketBeat, Johnson & Johnson presently has an average rating of “Moderate Buy” and an average target price of $213.33.

Johnson & Johnson Stock Down 0.3%

JNJ stock opened at $218.81 on Monday. The firm has a market cap of $527.18 billion, a PE ratio of 21.12, a P/E/G ratio of 2.25 and a beta of 0.34. Johnson & Johnson has a 12 month low of $141.50 and a 12 month high of $220.11. The company has a debt-to-equity ratio of 0.50, a current ratio of 1.07 and a quick ratio of 0.80. The firm has a 50 day simple moving average of $205.82 and a 200 day simple moving average of $187.17.

Johnson & Johnson Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 10th. Stockholders of record on Tuesday, February 24th will be paid a dividend of $1.30 per share. The ex-dividend date of this dividend is Tuesday, February 24th. This represents a $5.20 annualized dividend and a dividend yield of 2.4%. Johnson & Johnson’s dividend payout ratio (DPR) is currently 50.19%.

Johnson & Johnson Company Profile

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.